LifeWatch Receives CE Mark for Its LifeWatch V Health Smart Phone
07 Dec 2012
Neuhausen am Rheinfall/Switzerland - LifeWatch AG (SIX Swiss Exchange: LIFE),
the leading wireless remote cardiac and medical patient monitoring service
provider in the U.S., today reports that its LifeWatch V health smartphone
platform was awarded the CE Mark (Number 2074225CE02). The CE Mark allows
LifeWatch AG to launch its new LifeWatch V in Europe.
A CE mark confirms that the LifeWatch V system has met the applicable directives
of the European Commission (EC) and as such, can be marketed to the 30-nation
EEA and Switzerland. The LifeWatch V is a fully featured state-of-the-art
smartphone that allows patients and health- and wellbeing-conscious consumers to
self-operate a wide range of embedded medical sensors, wellness-related
applications, cloud-based services and 24/7 call center support.
By using the barely visible sensors on the phone's frame, patients and health-
and wellness consumers can track, capture, collect and analyze their health
measurements anywhere anytime. The sensors include ECG, body temperature, blood
glucose, heart rate, blood oxygen saturation, body fat percentage and stress
analysis measurement. All of the collected data can be retrieved from the cloud
for a follow-up. Users can take corrective action, plan diets and activities,
securely share the information with a health provider or family member, trend
and analyze the data and more. Patients may also program the LifeWatch V to
remind them of their drug type, dose and intake time.
The LifeWatch V handset unit includes a service enablement platform to support
the transmission of medical data to be analyzed, evaluated and communicated to
health professionals and call center personnel around the clock. The device
wirelessly interacts with a cloud-based environment allowing its' users direct
access to a wide range of complementary medical and wellness related services.
The LifeWatch V smartphone is an important milestone on the Company's way
towards more diversification into new service areas such as the consumer and
wellness markets and into new geographies.
"This is the first time in the company's history that a multi-parameter device
with five medical functions has been awarded the CE Mark", stated Dr. Yacov
Geva, Chairman of LifeWatch AG. "The approval demonstrates our capacity to
develop and manufacture devices that meet commercial regulatory requirements not
only in the U.S. but also in Europe and elsewhere".
LifeWatch is currently in discussions with a number of multi-national cell
carriers, pharmaceutical and healthcare providers all over the world on
partnership opportunities of the LifeWatch V.
About LifeWatch AG:
LifeWatch AG, headquartered in Neuhausen am Rheinfall and listed on SIX Swiss
Exchange (LIFE), Switzerland, is the leading healthcare technology and solution
company, specializing in advanced telehealth systems and wireless remote patient
monitoring services. LifeWatch services cater to individuals, ranging from
high-risk and chronically ill patients, to consumers of health and wellness
products. LifeWatch AG has operative subsidiaries in the United States, in
Switzerland and in Israel and is the parent company of LifeWatch Services Inc.,
and LifeWatch Technologies, Ltd. LifeWatch Services, Inc. is a leading US-based
provider of cardiac monitoring services and home sleep testing of Obstructive
Sleep Apnea (OSA). LifeWatch Technologies Ltd., based in Israel, is a leading
developer and manufacturer of telemedicine products. The Company is planning to
introduce the LifeWatch V, an Android-based smartphone with medical sensors and
apps that uses a cloud-based service platform. For additional information,
please visit { }[HYPERLINK: ].
Sign-up for customized email alerts and documentation requests is available at
This press release includes forward-looking statements. All statements other
than statements of historical facts contained in this press release, including
statements regarding future results of operations and financial position,
business strategy and plans and objectives for future operations, are
forward-looking statements. The words "believe," "may," "will," "estimate,"
"continue," "anticipate," "intend," "expect" and similar expressions are
intended to identify forward-looking statements. LifeWatch AG has based these
forward-looking statements largely on current expectations and projections about
future events and financial trends that it believes may affect the financial
condition, results of operations, business strategy, short term and long term
business operations and objectives, and financial needs. These forward-looking
statements are subject to a number of risks, uncertainties and assumptions. In
light of these risks, uncertainties and assumptions, the forward-looking events
and circumstances described may not occur and actual results could differ
materially and adversely from those anticipated or implied in the
forward-looking statements. All forward-looking statements are based only on
data available to LifeWatch AG at the time of the issue of this press release.
LifeWatch AG does not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new information,
future events or otherwise.
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.